Flutamide withdrawal plus hydrocortisone resulted in clinical complete response in a patient with prostate carcinoma

✍ Scribed by William D. Figg; Glenn Kroog; Paul Duray; McClellan M. Walther; Nicholas Patronas; Oliver Sartor; Eddie Reed

• Publisher: John Wiley and Sons
• Year: 1997
• Tongue: English
• Weight: 247 KB
• Volume: 79
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/(sici)1097-0142(19970515)79:10<1964::aid-cncr18>3.0.co;2-t

✦ Synopsis

METHODS.

A 71-year-old man with a positive family history of prostate carcinoma presented in 1989 with urinary frequency and a suspicious digital rectal examina-1 Clinical Pharmacology Branch, Division of tion. He was found to have a poorly differentiated adenocarcinoma (Gleason 4/4). Clinical Sciences, National Cancer Institute, He was started on CAB and his prostate specific antigen (PSA) concentration de-Bethesda, Maryland.

clined from 96 ng/mL to the normal range and was maintained for the next 24 2 Laboratory of Pathology, Division of Clinical months. In 1991 his PSA began to rise, and reached 64 ng/mL by 1993. The patient Sciences, National Cancer Institute , Bethesda, was enrolled on a clinical trial that discontinued the flutamide administration and Maryland.

hydrocortisone was initiated. 3 Surgery Branch, Division of Clinical Sciences, RESULTS. Physical examination at the time of enrollment was unremarkable. His